One-Dose CRISPR Treatment Cuts Cholesterol for Years in Animal Study

A single infusion of a CRISPR gene-editing treatment durably switched off a cholesterol-raising gene in monkeys for at least three years, according to a study published in Nature on 6 November. The research, led by scientists at Verve Therapeutics, now part of Eli Lilly, underpins a first-in-human clinical trial that is already under way in patients with hard-to-treat high cholesterol.

The treatment targets ANGPTL3, a gene in the liver that raises levels of LDL cholesterol, often called “bad” cholesterol, and triglycerides, two of the leading risk factors for heart attacks and strokes. The idea is a “one-and-done” therapy, rather than daily pills or regular injections.

How Does the Gene-Editing Treatment Work?

The therapy uses base editing, a precise form of CRISPR that changes a single DNA letter instead of cutting both strands of DNA. Guide RNA and messenger RNA for the base editor are packed into a tiny fat bubble, a lipid nanoparticle, carrying a sugar-based tag called GalNAc that steers it to liver cells.

Once inside the liver, the editor makes one base-pair change that disables the ANGPTL3 gene. Because the GalNAc tag uses a different entry route into liver cells, it is designed to work even in people whose LDL receptors do not function properly, such as those with the inherited condition homozygous familial hypercholesterolaemia, according to Verve.

What Did the Study Find?

• ANGPTL3 protein: more than 90% average reduction in the blood of non-human primates
• Durability: effect confirmed for 3 years after a single dose
• LDL cholesterol: about 40–50% lower in mouse and monkey models of high cholesterol
• Triglycerides: about 50–70% lower
• Safety checks: no detectable off-target editing at around 3,000 candidate sites tested in human liver cells

The authors wrote that the treatment was “well-tolerated” in monkeys. In earlier data, Verve reported only temporary rises in liver markers, which is typical for medicines delivered by lipid nanoparticles, and said these returned to normal within 14 days.

Why Does This Matter for Heart Disease?

Many patients on existing drugs, such as statins, never reach their target cholesterol levels, partly because treatment must be taken for life and people often stop. “Most patients fail to achieve target lipid levels under the chronic care treatment model,” the authors noted. A single treatment that lowers cholesterol permanently could help close that gap.

ANGPTL3 is a well-validated target. People born with natural mutations that disable the gene tend to have low cholesterol and triglycerides, and an antibody drug that blocks the ANGPTL3 protein is already approved for some patients. Gene editing aims to achieve the same effect permanently.

What Are the Limits and Next Steps?

The results come from animals and human liver cells, not patients, and the effects in people may differ. Gene editing is permanent, so long-term safety will need careful study, and it is not yet known how much the treatment will cost. The ongoing trial is in people with refractory hyperlipidaemia, meaning cholesterol that stays high despite existing treatments.

The study adds to fast-moving research on the biology behind major diseases, following other recent findings such as how a gut bacterium toxin attacks colon cells. Anyone worried about their cholesterol should speak to a doctor; diet, exercise and proven medicines remain the standard approach for now.

Featured image: A laboratory at the NIH Clinical Research Center, by Diane A. Reid / Wikimedia Commons, public domain. File photo; not the laboratory where the study was carried out.

Sources

• Nature — In vivo CRISPR base editing of ANGPTL3 for durable lipid lowering (6 November 2026).
• Verve Therapeutics — VERVE-201 programme overview (2026).
• European Heart Journal — An in vivo CRISPR base editing therapy to inactivate the ANGPTL3 gene: nomination of a development candidate for VERVE-201 (2022).